Clinical trials: Hemangioendothelioma
Hemangioendothelioma
Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma
The purpose of this study is to compare the efficacy and safety of different doses of sirolimus in the maintenance treatment of kaposiform hemangioendothelioma.
- Trial name
- NCT05324384
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 30 people
- Sponsor
- West China Hospital
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
This randomized phase II trial studies how well gemcitabine hydrochloride works with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01532687
- Testing
- Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Hemangioendothelioma of Liver
Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)
Infantile hepatic hemangioendothelioma (IHHE) is an infantile hemangioma involving the liver.Since 2008, propranolol has been used for the treatment of hemangioma, and some researchers have also started to report the use of…
- Trial name
- PRL-SRL-IHHE (NCT04406870)
- Testing
- Sirolimus Oral Product, propranolol
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Children's Medical Center
Solid Tumors, Adult, Solid Tumor
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally…
- Conditions
- Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE)
- Trial name
- NCT05228015
- Testing
- IK-930, Osimertinib
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- Ikena Oncology
Kaposiform Hemangioendothelioma, Kasabach Merritt Phenomenon
Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma
Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm that occurs predominantly in infancy or early childhood. KHE has a nearly equal sex ratio.
- Trial name
- NCT03188068
- Testing
- Sirolimus, Prednisolone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- West China Hospital
Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma
Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
- Trial name
- NCT04056962
- Testing
- Tacrolimus ointment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- West China Hospital
Kaposiform Hemangioendothelioma, Kasabach-Merritt Syndrome
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
This randomized controlled trial aims to compare guided discontinuation with maintenance treatment of sirolimus in pediatric patients with KHE.
- Trial name
- NCT04448873
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Fudan University
Kaposiform Hemangioendothelioma
Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
The purpose of this study is to compare the efficacy and safety of different concentration gradients of sirolimus in the treatment of Kaposiform hemangioendothelioma.
- Trial name
- NCT04775173
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 79 people
- Sponsor
- West China Hospital
Adipocytic Neoplasm, Liposarcoma
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin…
- Conditions
- Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma
- Trial name
- NCT06239272
- Testing
- Surgical resection, Proton beam radiation therapy, Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- St. Jude Children's Research Hospital
Epithelioid Hemangioendothelioma (EHE)
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment.
- Trial name
- NCT07104331
- Testing
- nab-Sirolimus
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Kaposiform Hemangioendothelioma
The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma
To research and explore the antibody protection and immune memory after vaccination in children with KHE during sirolimus administration.
- Trial name
- NCT05351216
- Where
- China
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Fudan University
Hemangioma, Kaposiform Hemangioendothelioma
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma in Chinese children by a prospective, randomized open trial.
- Trial name
- NCT04077515
- Testing
- Sirolimus(0.8mg/m2), Sirolimus(0.7mg/m2)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Children's Hospital of Fudan University
Angiosarcoma, Epithelioid Hemangioendothelioma
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin
- Trial name
- NCT03331250
- Testing
- Eribulin
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Epithelioid Hemangioendothelioma
A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
A Single-Arm, Non-Randomized, Open-Label Phase 2 Study of Nab-Sirolimus in Patients with Progressive or Symptomatic Epithelioid Hemangioendothelioma.
- Trial name
- NCT07684287
- Testing
- Sirolimus for injection (Albumin-bound)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Kaposiform Hemangioendothelioma, Tufted Angioma
Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies
In this study, we investigate the safety and efficacy of topical sirolimus in the treatment of superficial complicated vascular anomolies.
- Conditions
- Kaposiform Hemangioendothelioma, Tufted Angioma, Superficial Vascular Anomalies, Superficial Lymphatic Malformations
- Trial name
- NCT04921722
- Testing
- Percutaneous sirolimus, Oral sirolimus
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Children's Hospital of Fudan University
Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
This phase II trial studies how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body (metastatic), nearby tissue or lymph nodes (locally advanced), or cannot…
- Conditions
- Locally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma, Unresectable Epithelioid Hemangioendothelioma
- Trial name
- NCT03148275
- Testing
- Questionnaire Administration, Trametinib
- Where
- 36 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)